The funds will be used to develop medical membrane materials and premium catheters.
Shanghai ECO Polymer (Chinese:上海翊科) raised tens of millions of CNY from Qiming Venture Partners in a Series B financing round recently .
Previously, the company completed Series A financing round in 2021 worth of tens of millions of CNY; YuanBio Venture Capital and Blue Bay Capital are co-investors.
Founded in 2020 adn headquartered in Shanghai Zhangjiang Medical Device Science and Technology Park, the high-tech enterprise is committed to becoming a leading global premium medical consumables manufacturer. It has two 10,000-class purification plants in Zhangjiang and Lingang, Shanghai, and a 6,500 square-meter 10,000-class purification factory in Zhejiang.
Shanghai ECO currently focuses on providing downstream customers with complete solutions for medical membrane materials and catheters.
The company focuses on a series of application fields of medical membrane materials such as dialysis membranes and drug separation membranes. At present, it has cooperated with a number of downstream customers on dialysis membranes, and is fully prepared for the mass production of high-flux membranes.
The application fields of catheters cover multiple departments such as gastroenterology, cardiovascular and peripheral, neurointervention, urology and IVD (in-vitro diagnostics) testing. Its core products include nerve and peripheral microcatheters, disposable endoscopic catheters.
Shanghai ECO's R&D team has more than 20 years of experience in polymer material research and development, and has established close industry-university-research cooperation with many well-known universities.
"The localization of medical devices is overwhelming, and the demand for upstream materials for devices continues to expand. We are confident that Shanghai ECO will break the monopoly and help industrial upgrading," said Qiming Venture Partners.
The competitors of Shanghai ECO include Anjun Medical, Enove, Heyson Medical, Lonyi and Pukon.